Lynn Seely, Myovant CEO

My­ovant’s re­l­u­golix wins a piv­otal prostate can­cer show­down with an old stan­dard — com­ing down to the wire on ap­provals

My­ovant $MY­OV has round­ed the fi­nal turn in its de­vel­op­ment race to get re­l­u­golix down to the reg­u­la­to­ry wire at the FDA. And the biotech joined the vir­tu­al crowd at AS­CO with the kind of da­ta need­ed to keep the in­vestor crowd’s at­ten­tion.

Much of the at­ten­tion on the drug has been fo­cused on uter­ine fi­broids, where Ab­b­Vie just scored a reg­u­la­to­ry win for their ri­val drug Ori­ahnn (elagolix) as the biotech post­ed re­sults in prostate can­cer at the AS­CO meet­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.